Evocutis sells off skin substitute LabSkin

By Michelle Yeomans

- Last updated on GMT

Evocutis sells off skin substitute LabSkin

Related tags Human skin color Skin

Clinical research group Venn Life Sciences has acquired the rights to LabSkin, a skin substitute that behaves just like the real thing, as it moves to cater to cosmetics since the sweeping EU ban on animal testing.

Venn, which provides trial management services to the pharmaceutical sector acquired the intellectual property rights to the dermatology company's substitute.

The animal replacement technology emulates living skin with both dermal and epidermal layers. The epidermal layer is differentiated, which provides a dry, air-exposed surface to test all aspects of skin microbiology, according to Evocutis.

The dermatology brand is set to receive £210,000 (€255,783) in shares for LabSkin and will also receive 7.5% on the gross sales of the brand for the next three years.

As part of the deal, Venn also acquired SYN1113, which will also see the company receive a quarter of the royalties of future sales.

On the approval of Evocutis shareholders, the acquisition is expected to close at the end of the first quarter.

Sweeping animal ban has boosted labskin's success

UK-based Evocutis secured ten new contracts totalling £280,000 (€337,000) last year for its alternative method following a boost in demand for replacement technologies.

The contracts covered a variety of technology areas including the use of LabSkin to evaluate product interactions, microbiological evaluation of products on skin and prebiotic evaluation of products on skin microflora.

The substitute is a full thickness human skin model, comprised of both dermal and epidermal layers, providing a completely dry surface for tailored testing requirements.

It can be used to test a whole range of skin care products including moisturizers, anti-ageing products and anti-microbial agents, thus reducing the need for human and animal testing.

Catering to the industry with different models

Just last year the UK brand joined forces with Bradford University to develop models for different skin types and colours, allowing it to be used more widely in laboratories for research and development of personal care products.

The co-funded project investigated the addition melanocytes, the cells that produce melanin and gives skin and hair its colour, to LabSkin.

The commercial use of pigmented LabSkin would be to test and support the marketing claims of sun protection products.

Related topics Formulation & Science Skin Care

Related news

Show more

Related products

show more

Calendula Cellular Elixir: Alchemy in a cell

Calendula Cellular Elixir: Alchemy in a cell

Content provided by Naolys | 24-Apr-2024 | Product Brochure

Get ready to experience a cellular evolution in skincare with InnerLift Calendula's advanced Plant Cell biotechnology.

See our latest innovations in personal care

See our latest innovations in personal care

Content provided by Covation Bio™ PDO | 02-Apr-2024 | White Paper

At CovationBio PDO, we’re helping the world achieve its sustainability goals by enabling better performing, better-for-the planet products across a range...

Collagen Reimagined, Discover Biodesigned Type XXI

Collagen Reimagined, Discover Biodesigned Type XXI

Content provided by Geltor | 20-Mar-2024 | Product Brochure

Collagen is the body’s most abundant protein and a mainstream ingredient for beauty. Type XXI collagen transcends a common protein into a powerful bioactive

Empowering natural barrier function for future-proof skin

Empowering natural barrier function for future-proof skin

Content provided by Lucas Meyer Cosmetics | 14-Mar-2024 | White Paper

Corneopeptyl™ is a new patented peptide biomimetic to the LCE6A protein, obtained by green chemistry-based synthesis. By mimicking the LCE6A protein activity,...

Related suppliers